VetInject A/S

The company’s activity level has been fairly low as a result of the other activities in Injecto Group A/S, where Injecto Group A/S took over VetInject A/S back in 2023.The company still expects to base its business activities on the following basis and believes that the positive developments with respect to Injecto Group A/S’ subsidiary, Injecto A/S, which company focuses on primary packaging for human pharma, will contribute significantly to VetInject:Sales of lubrigone plunger stoppers included in pre-filled syringes (“PFS”) with preparations for animals with emphasis on dogs, cats and horses to syringe manufacturers, where such syringes are manufactured by other companies or by a subsidiary within the Injecto Group and the stoppers will be implemented as an integrated part of their product.Sublicense sales of lubrigone plunger stoppers and/or to companies producing veterinarian pharma.The plunger stoppers mentioned in points 1 and 2 above can be delivered by the licensor’s and parent company’s subsidiary, Injecto A/S. In this connection the company can benefit from the contacts established by the licensor and parent company and its associated companies with the pharmaceutical industry, where some of those contacts in addition to their production of medicinal preparations for humans also produce medicinal preparations for animals. The licensor's and parent company’s subsidiary, Injecto A/S’, established production line for plunger stoppers for 0.5 ml PFS in ISO in addition to the production line for stoppers for 1.0 ml (long) PFS strengthens the basis of the company’s business. Moreover, the ongoing implementation of the production line for plunger stoppers for 1-3 ml (2.25 ml) pre-fillable PFS will ensure that we can deliver in all three basic ISO measurements for PFS.Due to the licensor's and parent company’s expectation of establishing a larger production of easyject syringes based on the development of the co-operation with PATH (www.path.org) and attraction of funds for this production, the company has – at least for the time being - abandoned the plan of producing combined plunger rods and needle caps, as the company with the above mentioned production of the licensor will have the opportunity to sell an entire syringe for prefilling in the form of easyject at a competitive price. The additional, thorough tests performed by PATH are expected to postpone the establishment of the production line of easyject.The company foresees an increasing potential for pre-fillable syringes for veterinarian use, partly supported by the increasing number of zoonotic diseases and underpinned by the world-wide focus on those following the COVID-19 pandemic.Furthermore, the market for PFS for animals has been growing and will continue to grow, cf. the following links:https://www.mask-makingmachine.com/news/unveiling-the-role-of-veterinary-prefilled-syringes-as-a-critical-innovation-in-animal-healthcare-pr-279856.htmlhttps://www.360iresearch.com/library/intelligence/veterinary-prefilled-syringesFrom the last link is referred to the following graphical illustration:The constantly growing market gives VetInject A/S a good opportunity for a successful entrance based on its products’ competitive advantages where the PFAS free solution is a compelling sales argument.